A new trading day began on Monday, with Verrica Pharmaceuticals Inc (NASDAQ: VRCA) stock price down -5.94% from the previous day of trading, before settling in for the closing price of $1.01. VRCA’s price has ranged from $0.70 to $11.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -13.60%. Meanwhile, its annual earnings per share averaged -3.55%. With a float of $49.14 million, this company’s outstanding shares have now reached $90.56 million.
Let’s determine the extent of company efficiency that accounts for 100 employees. In terms of profitability, gross margin is 72.9%, operating margin of -815.5%, and the pretax margin is -922.81%.
Verrica Pharmaceuticals Inc (VRCA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 45.74%, while institutional ownership is 16.50%. The most recent insider transaction that took place on Aug 26 ’24, was worth 69,647. In this transaction CHIEF LEGAL OFFICER of this company sold 26,183 shares at a rate of $2.66, taking the stock ownership to the 115,303 shares. Before that another transaction happened on Aug 27 ’24, when Company’s CHIEF LEGAL OFFICER sold 9,530 for $2.46, making the entire transaction worth $23,444. This insider now owns 105,773 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.55% per share during the next fiscal year.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Here are Verrica Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.83, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Looking closely at Verrica Pharmaceuticals Inc (NASDAQ: VRCA), its last 5-days average volume was 0.77 million, which is a jump from its year-to-date volume of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 33.96%. Additionally, its Average True Range was 0.14.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 3.36%, which indicates a significant decrease from 26.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.27% in the past 14 days, which was lower than the 161.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2185, while its 200-day Moving Average is $4.7823. However, in the short run, Verrica Pharmaceuticals Inc’s stock first resistance to watch stands at $1.0167. Second resistance stands at $1.0833. The third major resistance level sits at $1.1167. If the price goes on to break the first support level at $0.9167, it is likely to go to the next support level at $0.8833. Should the price break the second support level, the third support level stands at $0.8167.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
With a market capitalization of 86.04 million, the company has a total of 45,601K Shares Outstanding. Currently, annual sales are 5,120 K while annual income is -67,000 K. The company’s previous quarter sales were 5,180 K while its latest quarter income was -17,190 K.
